DRMA
DRMA
NASDAQ · Biotechnology

Dermata Therapeutics Inc

$1.24
+0.03 (+2.48%)
Financial Highlights (FY 2025)
Revenue
2.63M
Net Income
21.2K
Gross Margin
52.3%
Profit Margin
0.8%
Rev Growth
-5.2%
D/E Ratio
0.27
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 52.3% 52.3% 52.3%
Operating Margin 1.0% 1.0% 0.8%
Profit Margin 0.8% 0.8% 0.7%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 2.63M 2.53M 2.93M
Gross Profit 1.38M 1.32M 1.54M
Operating Income 25.8K 25.5K 23.8K
Net Income 21.2K 20.0K 19.6K
Gross Margin 52.3% 52.3% 52.3%
Operating Margin 1.0% 1.0% 0.8%
Profit Margin 0.8% 0.8% 0.7%
Rev Growth -5.2% +23.9% +20.0%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 946.2K 972.0K 952.2K
Total Equity 3.56M 3.67M 3.72M
D/E Ratio 0.27 0.26 0.26
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 30.9K 30.5K 37.6K
Free Cash Flow 17.8K 22.0K 24.1K